Drug Trial Radar · NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
Sep 18, 2023
Primary completion
Apr 19, 2033
Study completion Apr 19, 2033
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Feb 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of their myeloma (shrinkage of their tumors), including some participants who had complete responses (that is, the treatment got rid of all evidence of myeloma in their bodies). This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of this study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone, (called EPd) in participants who have returned after having received prior treatment that included lenalidomide, a proteosome inhibitor, and (for participants in some countries) a cluster of differentiation 38 (CD38) antibody. Half of the participants in this study will get linvoseltamab, and the other half will get EPd. This study is looking at several other research questions, including: * How long participants benefit from receiving linvoseltamab compared with EPd * How many participants treated with linvoseltamab or EPd have improvement of their multiple myeloma and by how much * What side effects happen from taking linvoseltamab compared to EPd * How long participants live while receiving treatment or after treatment with linvoseltamab compared to EPd * If there is any improvement in pain after treatment with linvoseltamab compared to EPd
Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
LinvoseltamabDrug
REGN5458 will be administered by intravenous (IV) infusion
ElotuzumabDrug
Elotuzumab will be administered by IV infusion
PomalidomideDrug
Pomalidomide capsules will be administered by mouth (PO)
DexamethasoneDrug
Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participantsTime frame: Up to approximatively 5 years
Locations
159 sites in 18 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA)
Los Angeles, California · Active not recruiting
University of Florida Division of Sponsored Programs
Gainesville, Florida · Withdrawn
University of Kentucky, Markey Cancer Center Clinical Research Organization
Lexington, Kentucky · Active not recruiting
Norton Cancer Institute
Louisville, Kentucky · Active not recruiting
Stony Brook University
Stony Brook, New York · Active not recruiting
Levine Cancer Center
Charlotte, North Carolina · Active not recruiting
Duke University Medical Center
Durham, North Carolina · Withdrawn
Kaiser Permanente Northwest
Portland, Oregon · Active not recruiting
MD Anderson Cancer Center
Houston, Texas · Active not recruiting
University of Washington
Seattle, Washington · Active not recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Active not recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Active not recruiting
Icon Cancer Centre - Wesley
Auchenflower, Queensland, Australia · Active not recruiting
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Active not recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Active not recruiting
Royal Hobart Hospital
Hobart, Tasmania, Australia · Active not recruiting
Launceston General Hospital
Launceston, Tasmania, Australia · Active not recruiting
St Vincent's Hospital
Fitzroy, Victoria, Australia · Active not recruiting
University Hospital Geelong
Geelong, Victoria, Australia · Active not recruiting
Austin Hospital
Heidelberg, Victoria, Australia · Active not recruiting
One Clinical Research at Hollywood Private Hospital
Nedlands, Western Australia, Australia · Active not recruiting
Ziekenhuis Netwerk Antwerpen Stuivenberg
Antwerp, Belgium · Active not recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Withdrawn
Clinique Universitaire de Mont Godinne
Yvoir, Namur, Belgium · Completed
AZ Delta Algemeen Ziekenhuis Delta
Roeselare, West-Vlaanderen, Belgium · Active not recruiting
Instituto Americas de Ensino e Pesquisa
Rio de Janeiro, Brazil · Active not recruiting
A Beneficencia Portuguesa de Sao Paulo, Oncology House
São Paulo, Brazil · Active not recruiting
Instituto DOr de Pesquisa e Ensino
São Paulo, Brazil · Active not recruiting
AC Camargo Cancer Center
São Paulo, Brazil · Active not recruiting
Clinica Medica Sao Germano
São Paulo, Brazil · Active not recruiting
IDOR - Sao Rafael Salvador Bahia
Salvador, Estado de Bahia, Brazil · Active not recruiting
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil · Active not recruiting
Associacao Dr Bartholomeu Tacchini
Bento Gonçalves, Rio Grande do Sul, Brazil · Active not recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
Centro Gaucho Integrado
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
Animi Unidade de Tratamento Oncologico
Lages, Santa Catarina, Brazil · Active not recruiting
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada · Active not recruiting
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada · Active not recruiting
University Health Network-Princess Margaret Cancer Center
Toronto, Ontario, Canada · Active not recruiting
Hospital Clinico Universidad de Los Andes
Santiago, Las Condes, Chile · Active not recruiting
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.